entertainment -WSS

entertainment

author：Wikipedia 2025-09-06 01:59:34 - browse：44126

A product image of the Cue reader COVID-19 home use test — Businesswire via AP

The Food and Drug Administration warned consumers Monday to not use Cue Health’s at-home Covid-19 tests. This follows an FDA warning letter to the company last week that said Cue was not following the conditions stipulated in the emergency use authorizations for its tests.

The FDA letters said the tests could give false results. Specifically, the agency said that the company had changed how the electrochemical signals within the test device were generated, received, and interpreted — changes the FDA has not authorized. These changes decreased the stability of the tests and might lead to false results, the agency said.

The FDA warnings come near what might be the end of a spectacularly bumpy ride for the company. When Cue went public in 2021, it was valued at nearly $3 billion. It supplied tests for the NBA’s 2020 “bubble,” leading a Trump administration official to proclaim that if the test was “good enough for LeBron,” the administration would bring it to the American people — and it did, in a $481 million deal.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

focus

WSS

How to save health care price transparency rules

Sarepta Duchenne therapy fails to meet primary endpoint in trial

Medicare must police algorithms in Medicare Advantage, Dems say

Gene therapy’s promise and the high cost of hope

Readout LOUD podcast: ESMO highlights & Roivant's big deal

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

Wikipedia

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

focus

Virginia high school admissions case could be legal follow

Travis Kelce and the trap of celebrity vaccine endorsements

Cancer drug shortages should be causing more outrage

Prime Medicine says its gene editing passes test in monkeys

Continuity nursing helped my family in our darkest PICU moments

How to convince healthy people to buy insurance

23andMe had bad news about my health. I wish a person had delivered it

Medicare must police algorithms in Medicare Advantage, Dems say

DIEP, the 'gold standard' of breast reconstruction, is under threat

Kidney transplant patients stopped immunosuppressants in trial

explore

First U.S. drug developed to treat liver disease MASH is approved

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

As AI in medicine takes off, can 'human in the loop' prevent harm?

Boston's new lab space is opening empty

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

How many hemophilia patients actually want gene therapy?

focus

focus

Wikipedia

Wikipedia